Home>Topics>Stocks>C.R. Bard

C.R. Bard

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. CR Bard Bolsters Narrow Moat With Technology That Appeals to Hospitals Seeking Efficiencies

    Commentary

    Mon, 25 Aug 2014

    We have long appreciated CR Bard 's narrow economic moat and have recently taken another look at the firm's product portfolio and general approach to navigating

  2. 2 Key Tests For The True Dividend Growth Investor

    Headlines

    Thu, 14 Aug 2014

    By Eric Parnell, CFA : It is one of the most popular and time-tested stock market investment strategies. It is dividend growth investing, or DGI, which is a strategy that focuses on companies that consistently increase their dividend payouts each year, supported by the predictable long-term growth

  3. Fitch Revises BCR's Outlook to Negative; Affirms at 'BBB+'

    Headlines

    Tue, 12 Aug 2014

    based Banca Comerciala Romana S.A.'s ( BCR ) Long-term foreign and local currency ..... at 'F2' and Support Rating at '2'. BCR 's Viability Rating (VR) was not affected ..... RATING DRIVERS: IDRs AND SUPPORT RATING BCR 's IDRs and Support Ra

  4. New Morningstar Analyst Report for CR Bard Inc

    Stock Reports

    Tue, 29 Jul 2014

    substantial market share decline for Bard. C . R . Bard 's line of infection-control products ..... when capital spending is low. We rate C . R . Bard 's stewardship as Standard. Chairman ..... lower executive compensation rates than C . R . Bard . We also would like to see more disclosure

  5. CR Bard's ( BCR ) CEO Timothy Ring on Q2 2014 Results - Earnings Call Transcript

    Headlines

    Thu, 24 Jul 2014

    CR Bard (NYSE: BCR ) Q2 2014 Earnings Call July 24, 2014 5:00 pm ET Executives Timothy M. Ring - Chairman, Chief Executive Officer and Chairman

  6. C. R . Bard beats by $0.18, beats on revenue

    Headlines

    Thu, 24 Jul 2014

    C . R . Bard (NYSE: BCR ): Q2 EPS of $2.06 beats by $0.18 . Revenue of $827.1M (+8.8% Y/Y) beats by $12.52M . Press Release Post your comment!

  7. Boston Scientific Exceeds Our Expectations in the Second Quarter

    Commentary

    Thu, 24 Jul 2014

    in constant currency, propelled by urology and women's products. Moreover, the electrophysiology business purchased from CR Bard provided a boost by rounding out Boston's portfolio with complementary products. Boston held gross margin steady at 70

  8. New Morningstar Analyst Report for Endo International PLC

    Stock Reports

    Thu, 19 Jun 2014

    facing lawsuits related to patient injuries caused by its vaginal mesh products. The issue is not unique to Endo--competitors CR Bard , Boston Scientific, Johnson & Johnson, and others are facing litigation for similar products--but it could face a significant

  9. CR Bard Sees Boost in First Quarter Thanks to Gore Royalties and Acquisitions

    Commentary

    Tue, 22 Apr 2014

    CR Bard reported first-quarter results that slightly exceeded our expectations, thanks to acquisitions made last year as well as royalty

  10. CR Bard Underlying Business Remains Solid in Fourth Quarter

    Commentary

    Fri, 31 Jan 2014

    CR Bard released solid fourth-quarter performance that generally matched our expectations, and we are leaving our fair value estimate

« Prev1234Next »
Content Partners